{"filing":{"accession_number":"0001104659-26-092691","cik":"0001175151","ticker":"CTSO","company_name":"Cytosorbents Corp","form":"8-K","filing_date":"2026-08-07","report_date":"2026-08-06","primary_document":"tm2622604d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1175151/000110465926092691/tm2622604d1_8k.htm"},"events":[{"id":26093,"run_id":23693,"accession_number":"0001104659-26-092691","anchor_item_number":"7.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The Item 7.01 disclosure furnishes a Q2 2026 earnings conference call presentation (Exhibit 99.1) dated August 6, 2026, which includes financial results, operational updates, and forward-looking guidance. The presentation explicitly references \"Q2 2026 Revenue\" of $9.6M, operating cash burn metrics, gross margins of 73%, and discusses progress toward operating cash flow breakeven in H2 2026. While technically filed under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02, the substance is a quarterly earnings presentation with material financial results and operational performance metrics.","company_name":"Cytosorbents Corp","ticker":"CTSO","filing_date":"2026-08-07","form":"8-K","submitted_at":null,"items":[{"id":27105,"accession_number":"0001104659-26-092691","item_number":"7.01","item_title":"Regulation","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Item 7.01 disclosure furnishes a Q2 2026 earnings conference call presentation (Exhibit 99.1) dated August 6, 2026, which includes financial results, operational updates, and forward-looking guidance. The presentation explicitly references \"Q2 2026 Revenue\" of $9.6M, operating cash burn metrics, gross margins of 73%, and discusses progress toward operating cash flow breakeven in H2 2026. While technically filed under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02, the substance is a quarterly earnings presentation with material financial results and operational performance metrics.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:05:52.308563+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27105,"accession_number":"0001104659-26-092691","item_number":"7.01","item_title":"Regulation","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Item 7.01 disclosure furnishes a Q2 2026 earnings conference call presentation (Exhibit 99.1) dated August 6, 2026, which includes financial results, operational updates, and forward-looking guidance. The presentation explicitly references \"Q2 2026 Revenue\" of $9.6M, operating cash burn metrics, gross margins of 73%, and discusses progress toward operating cash flow breakeven in H2 2026. While technically filed under Item 7.01 (Regulation FD Disclosure) rather than Item 2.02, the substance is a quarterly earnings presentation with material financial results and operational performance metrics.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T03:05:52.308563+00:00","company_name":"Cytosorbents Corp","ticker":"CTSO","filing_date":"2026-08-07"}]}